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ABSTRACT 
 
 Plasma membrane (PM) association is an essential step in the retroviral life 
cycle that involves the complex association of the Gag polyprotein with cellular 
machinery, RNA, and specific lipid signatures of the inner leaflet. Here, I describe the 
first systematic comparison of Equine Infectious Anemia Virus (EIAV), Human 
Immunodeficiency Virus Type 1 (HIV-1), and Rous Sarcoma Virus (RSV) Gag 
membrane binding properties using in vitro liposome binding assays, in vivo virus 
release assays, and localization studies using confocal microscopy of 293T cells. By 
doing so, I hoped to address two main questions. First, what drives EIAV Gag 
association with the plasma membrane? And second, why is EIAV Gag not 
myristoylated? My results showed that EIAV Gag membrane association is driven by 
electrostatic interactions and a preference for cholesterol-containing membranes. 
These results highlight the universal importance of electrostatic interactions for 
retroviral Gag PM targeting and may underline a shared association with lipid raft 
microdomains for budding. I also used EIAV matrix (MA) and HIV-1 MA mutants to 
confirm HIV-1’s dependence on myristoylation for virus release and localization to 
the plasma membrane. These same mutants have also led me to propose a model for 
EIAV MA helix 1 inhibition of myristoylation. Finally, a part of my thesis work has 
been dedicated to the development of a novel silica-bead binding assay to study 
protein-lipid interactions. I describe this work in Appendix 1.  
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INTRODUCTION 
 
The multidomain polyprotein Gag is the main structural protein that 
organizes essential interactions with RNA, lipids, host cellular machinery, and itself 
for the assembly and budding of new retrovirus particles. The Gag protein contains 
three major domains: matrix (MA), capsid (CA), and nucleocapsid (NC). The MA 
domain controls Gag localization to the plasma membrane (PM); the CA domain 
mediates Gag-Gag interactions and the formation of immature virus particles; the 
NC domain coordinates viral genomic RNA packaging.  
The big picture goal of my work was to further our understanding of the lipid 
signatures that drive Gag’s recognition of and localization to the inner leaflet of the 
PM. Two phospholipid species of particular importance to retrovirus assembly are 
phosphatidylserine (PS) and phosphatidylinositol phosphates (PIPs).  PS—which 
constitutes around 25-35% of inner leaflet phospholipids—has a single -1 charge 
that contributes to a large portion of the overall, asymmetric acidity of the PM, and 
is therefore important in directing the localization of proteins with polybasic 
regions, such as Gag (1, 2, 3, 4). PIPs have multiple negative charges that depend on 
specific regulation by kinases and phosphatases in different cellular compartments 
(5, 6). This variable distribution of PIPs in membrane compartments has been 
shown to be important for retrovirus trafficking (7,8), and like PS, for the 
localization of Gag to the plasma membrane (3, 9, 10, 11, 12, 13).  
The primary interaction of Gag with membranes is through its membrane-
binding domain (MBD) at the N-terminus of MA. Though retrovirus MBD sequences 
have largely diverged from each other, previous studies have shown MBD structural 
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homology and conserved basic surface patches that underline the universal 
importance of electrostatic interactions for Gag localization to the PM (4, 14, 15). It 
has also been suggested that retroviruses, such as Human Immunodeficiency Virus 
Type 1 (HIV-1) and Rous Sarcoma Virus (RSV), bud through lipid rafts, lipid 
microdomains with high liquid order phases that are enriched in unsaturated lipids, 
cholesterol and sphingomyelin (SM) (16, 17). Recent scholarship has also 
highlighted Gag’s preferential targeting to unsaturated lipids, as well as its ability to 
distinguish acyl chain saturation and increased cholesterol concentration (18).  
I began to investigate the importance of these different lipid criteria for 
retrovirus assembly and budding by comparing the Gag-membrane binding 
properties of HIV-1, RSV, and with a particular focus on Equine Infectious Anemia 
Virus (EIAV). Due to its relevance on human health, the majority of retroviral Gag-
membrane interactions has been studied with HIV-1, which is, the best understood 
of these three viruses. HIV-1 membrane binding is governed by three features: a 
basic surface patch, a specific binding pocket for PI(4,5)P2, and a 14-carbon fatty 
acid chain myristate group that is attached to a Glycine residue at the N-terminus of 
MA (3, 8, 9, 10, 11, 12, 13, 15). In vitro liposome flotation assays have shown that 
HIV-1 Gag binding is contingent upon, and greatly enhanced by an acidic lipid 
environment (3, 15, 18). Indeed, mutations in this basic surface patch cause 
mislocalization of Gag and a decrease in virus like particle (VLP) production (19, 
20). Similarly, phosphatase-mediated depletion of PI(4,5)P2 in vivo decreases both 
HIV-1 Gag localization to the PM and VLP production (3).  
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N-terminal myristoylation is the co-translational or post-translational 
addition of a myristate group to Glycine residues at the second position after 
removal of the initiating Met by N-myristoyltransferase (NMT) (21, 22, 23, 24). 
Though myristoylation comprises only ~1% of all fatty acids in cells, its length and 
saturation is uniquely capable of allowing proteins to reversibly interact with 
membranes (23, 24). Additional fatty acid modifications such as palmitoylation, or 
electrostatic interactions are needed for stable fixing to membranes (23, 24). Thus, 
HIV-1 Gag relies on electrostatic interactions and specific binding to PI(4,5)P2 to 
position and secure the N-terminal myristate group into a favorable position for 
insertion into the lipid bilayer, thereby anchoring HIV-1 MA in the PM (13, 20, 23, 
24). 
Unlike HIV-1, however, RSV lacks both a myristate group and a specific 
PI(4,5)P2 binding pocket. Though the addition of PI(4,5)P2  or other PIP species 
enhances membrane binding in vitro, RSV MA appears to rely solely on electrostatic 
interactions between its basic surface patch and acidic lipid head groups for 
targeting to the PM (3, 14); depletion of PI(4,5)P2  does not cause RSV Gag 
mislocalization, nor does it cause a significant decrease in VLP release (3).   
Of these three retroviruses, EIAV biology and its membrane binding 
requirements are the least well understood. As with other retroviruses, EIAV begins 
its life cycle by binding to a cellular receptor (the identity of which has yet to be 
discovered) on horse macrophage cells with its envelope glycoprotein gp90 (25). 
Attachment to the cell leads to membrane fusion, and release of the EIAV capsid into 
the cytoplasm where the viral RNA is reverse transcribed into DNA, imported into 
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the nucleus, and integrated into the genome by the viral integrase (25). Rev-
mediated nuclear export of transcripts allows for the translation of viral proteins in 
the cytoplasm that then target the plasma membrane for the assembly of new virus 
particles (25). Though the genomic organization of EIAV is very similar to that of its 
lentivirus relatives, EIAV infection in vivo displays a unique immunological 
phenotype. While lentiviruses such as HIV-1 are characterized by lifelong, 
degenerative disease, EIAV infected equids are able to transition from a chronic 
stage of cyclical disease to an asymptomatic state, wherein the animals no longer 
display disease symptoms, but are still able to transmit EIAV to non-infected 
animals (25, 26, 27). As a result, there is increasing interest in the potential of using 
EIAV as a potential model system in understanding vaccine designs for other 
lentiviral infections (25, 26, 27).  
Like RSV Gag, EIAV Gag has been reported to not be myristoylated despite 
having a Glycine residue at the second position (28,29). A crystal structure of EIAV 
MA from 2002 showed that despite limited sequence similarity, EIAV MA likewise 
contains a basic surface patch and remarkable structural homology to both HIV-1 
and Simian Immunodeficiency Virus (SIV) MAs (30), The current model for EIAV MA 
binding, based on EIAV MA crystal structure (30), and previous EIAV MA-lipid 
fluorescence anisotropy measurements (31), have suggested that EIAV MA interacts 
with the inner leaflet through electrostatic interactions and the insertion of a mobile 
helical hinge that partitions into the membrane head group region. This model also 
suggests that EIAV MA can interact with the PM with both a basic surface patch and 
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can roll over on the membrane surface to expose a hydrophobic face that interacts 
with neutral membranes (31).  
Therefore, for my honors thesis, I hoped to address two main questions 
about EIAV Gag membrane binding. First, what drives EIAV Gag to associate with 
the plasma membrane? Is EIAV, like RSV, driven to the PM by electrostatic 
interactions? And if so, is the model put forth by Provitera et al. and others correct? 
That is, can EIAV Gag also interact with electrically neutral membranes?  To 
investigate these questions, I conducted a systematic comparison of EIAV Gag 
binding with HIV-1 and RSV Gag binding to five different lipid compositions in an in 
vitro liposome-binding assay with 35S radiolabeled proteins.  
Second, why is EIAV Gag not myristoylated? If myristoylation does in fact 
enhance membrane binding and VLP production, as in HIV-1 (12, 32), why has EIAV 
evolved to exclude the addition of this moiety at its N-terminus?  To address these 
questions, I made a series of point mutations at key residues in EIAV MA, along with 
corresponding mutations in HIV-1 MA, that have been shown to inhibit or restore 
myristoylation in other proteins. I investigated the effects of these mutations on 
myristoylation in an in vitro rabbit reticulocyte expression system in the presence 
of radiolabeled 3H-myristic acid. I also used in vitro liposome binding assays to 
assess the effects of these mutations on Gag-membrane binding. Finally, I measured 
VLP production in transfected 293T cells by western blot and used confocal imaging 
of Gag-GFP to look at changes in distribution due to these mutations.    
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A part of my thesis research was dedicated to the development of a novel 
silica bead binding assay to test protein-lipid interactions. I discuss my work on this 
project in Appendix I.  
 
MATERIALS AND METHODS 
DNA constructs 
A pPRE/EIAV Gag expression vector was generously provided by Eric Freed 
(NIH) for this study. I PCR amplified EIAV WT Gag sequence out of pPRE/EIAV and 
cloned it into pET3xc using EcoRI (nucleotide [nt]4100) and XbaI (nt6045) cut sites 
for T7-driven TNT reticulocyte lysate system (Promega) expression. All subsequent 
EIAV Gag mutants for use in this system were created using PCR-site directed 
mutagenesis from this initial construct. HIV-1 Gagp6 (BH-10), HIV-1 Gagp6 
G2A(BH-10), and RSV GagPR were provided by Rob Dick (Cornell University). 
pET3xc-HIV A3D Gag was constructed using PCR-site directed mutagenesis using 
NdeI (nt4088) and KpnI (nt5441) cut sites.  
EIAV and HIV-1 cell culture constructs were made by PCR amplifying the 
corresponding sequences out of their respective pET3xc plasmids into a pEGFP-N1 
vector (Clontech) using EcoRI (nt629) and BamHI (nt2201) cut sites. pEGFP-N1-HIV 
Gag (BH10) was provided by Rob Dick (Cornell University) while pEGFP-N1-HIV 
Gag G2A (BH10) was provided by Marc Johnson (Cornell University). A full list of 
constructs and primers used in this study can be found in Supplementary Table 1.  
 
Liposome Preparation 
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Liposomes were prepared using rapid solvent exchange as described (18, 
33). Chloroform solutions of purified 1-Palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine [POPC], 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine 
[POPS], cholesterol [Chol], and L--phosphatidylinositol-4,5-bisphosphate [brain 
PI(4,5)P2] were mixed to make five lipid solutions: 100%POPC, 70%POPC: 
30%POPS, 34%POPC: 30%POPS:36% Chol, and 68%POPC: 30%POPS: 2%PI(4,5)P2. 
20 mM HEPES, pH 7.0 buffer was added to the lipid solutions in glass tubes, 
vortexed under vacuum for 90 seconds, and sealed under Argon gas to yield large 
unilamellear vesicle (LUV) solutions at 10 mg/mL. Hydrated liposomes were 
extruded in a mini-extruder block (Avanti) for no less than 60 times through 100-
nm-polycarbonate filters (Avanti) to homogenize liposome species. All liposomes 
were stored at 4C and used within 2 weeks.  
 
Reticulocyte Expression Tests and Liposome Binding Assay 
Radioactively labeled proteins were made in TNT coupled T7 rabbit 
reticulocyte reactions (Promega) in the presence of [35S] Metionine/Cysteine 
(Perkin-Elmer; ExPRE35S35 protein labeling mix), Myristic Acid [9,10-3H(N)]-
(tetradecanoic acid) (Perkin-Elmer), or both. Reticulocyte reactions were incubated 
for 90 min at 30C. Reticulocyte expression tests were carried out in 12.5 L or 25 
L formats and run on SDS-PAGE. Gels were incubated for 30 min in 1 M sodium 
salicylate, dried, and developed on film at -80C for 3-6 h (35S) or up to 2 weeks (3H-
myr).  
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Liposome binding assays were conducted as previously described (3, 18). 5 
L of each reticulocyte reaction was incubated with 15 L binding buffer (20 mM 
HEPES, pH 7.0) and 50 g of LUVs at room temperature for 10 min. 80 L of a 67% 
wt/wt sucrose (20 mM HEPES, pH 7.0) solution was then mixed with each binding 
reaction. 80 L of this mix was then placed in a TLA-100 ultracentrifuge tube 
(Beckman), and layered with 120 L 40% wt/wt sucrose (20 mM HEPES, pH 7.0), 
and 40 L 4% wt/wt sucrose (20 mM HEPES, pH 7.0) solutions.  Binding mixtures 
were centrifuged at 90,000 rpm in a TLA-100 rotor (Beckman) for 1 h. Four 60-L 
fractions were collected from each reaction and resolved by SDS-PAGE. Gels were 
then incubated for 30 min in 1 M sodium salicylate, dried, and developed on film at -
80C for 16-48 h. The resulting autoradiograms were scanned and analyzed using 
ImageQuant software. The first two fractions represented liposome-bound Gag 
while the bottom two fractions represented non-liposome bound Gag. No less than 
three independent experiments were conducted for each construct and lipid type. 
Results were averaged and graphed using Prism 5(GraphPad Software Inc.). Error 
bars represent standard deviations from the mean.  
 
Cells and Transfection 
293T cells were cultured and maintained in Dulbecco’s Modified Eagle 
Medium supplemented with 5% Fetal Bovine Serum, 5% NuSerum (BD Biosciences), 
and standard vitamins. 293T cells were seeded onto glass coverslips for confocal 
imaging or six-well plates for virus release assays 24 h prior to transfection. Cells 
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were transfected at 50% confluence with 2 g DNA with FuGENE HD (Roche) per 
manufacturer’s instructions.  
 
Virus release and Western Blotting 
To conduct virus release measurements, medium and cells were collected 
24h post-transfection. The medium was centrifuged for 5 min at 5,000 x g  to 
remove any cellular debris. Cells were collected by re-suspension in 300 L of 
1xSDS loading buffer. The collected media was then underlaid with 0.50 mL of virus 
suspension buffer (15% sucrose in 20 mM Tris-HCl [pH 7.5], 100 mM NaCl, 10 mM 
EDTA) to isolate virus-like particles (VLPs). The mixtures were then centrifuged at 
90,000 rpm for 30 min in a TLA 110 rotor (Beckman). Resulting pellets were 
resuspended in 100 L of 1x SDS loading buffer.  
Samples were run on SDS-PAGE and transferred to a nitrocellulose 
membrane. Primary antibody rabbit anti-GFP, N-term (Sigma) diluted 1:2,000 
followed by secondary anti-rabbit IgG-Horseradish Peroxidase (Amersham 
Pharmacia Biotech UK Limited) diluted 1:10,000. ChemiGlow reagent (Alpha 
Innotech) was added and blots were visualized by film. EIAV and HIV Gag bands 
were analyzed and quantified by ImageQuant software. Results were averaged and 
graphed using Prism 5(GraphPad Software Inc.). Error bars represent standard 
deviations from the mean. Statistical Significance was calculated using an unpaired 
student’s t-test with p<0.05.  
 
Confocal Microscopy 
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293T cells were collected 24 h after transfection and fixed with 3.7% 
formaldehyde in PBS for 15 min. Cells were mounted on glass slides with Fluoro-Gel 
(Electron-Microscopy Sciences) for imaging by Ultraview-spinning disc confocal 
microscope (Perkin-Elmer) with a Nikon 100x Plan-Apochromat oil objective lens 
(numerical aperture[NA] 1.4). Images were analyzed and generated with ImageJ 
software.  
 
RESULTS 
 
HIV-1, RSV, and EIAV Gag bind similarly to Liposomes containing POPS and 
Cholesterol 
 
To understand the lipid signatures that drive EIAV Gag to the PM, I conducted a 
series of liposome flotation reactions and compared EIAV Gag binding with HIV-1 
and RSV Gag binding. Example autoradiograms of flotations can be seen in Fig. 1A. 
EIAV Gag binding to 70%POPC:30%POPS liposomes was ~26%; binding increased 
to ~36% against 34%POPC:30%POPS:36%Chol liposomes (Fig. 1B). Similar trends 
were seen with HIV-1 and RSV Gag and were in accordance to results reported from 
previous studies (Fig. 1A-B) (3,18). Addition of 36% Cholesterol enhanced binding 
of EIAV Gag to 36%% therefore suggesting that like HIV-1 and RSV, EIAV Gag 
prefers regions of the plasma membrane with higher cholesterol concentrations 
(18). This also indicates that EIAV may associate with lipid raft microdomains, as 
inferred for HIV-1 (16, 17, 18, 34, 35) and RSV (14, 35, 36).  
 
EIAV MA N-terminal mutations show no effect on membrane binding 
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N-myristoylation is the addition of a 14C saturated fatty acid chain to Glycine 
residues at the N-terminus of proteins by NMT (21, 22, 23, 24). The consensus 
sequence for N-myristoylation is generally considered to be Met-Gly-X-X-X-Ser/Thr-
X-X (21, 22). Yet, despite having the necessary Glycine at the N-terminus, and a Thr 
at residue 5, EIAV is widely accepted to not be myristoylated (28, 29). In accordance 
with a study by Utsumi et al (21), I hypothesized that residues at the 3rd and 4th 
position of EIAV MA may inhibit myristoylation. To test this hypothesis, I 
constructed four EIAV Gag mutations, as well as corresponding mutations in HIV-1 
(Fig. 2A), and measured the effects of these mutations on EIAV Gag (Fig. 2B) and 
HIV-1 Gag (Fig. 2C) binding to liposomes. I predicted that the addition of 
myristoylation would increase the hydrophobicity of Gag and therefore increase 
membrane binding.  
The first mutant was an EIAV G2A mutation (Fig. 2A). If EIAV is indeed not 
myristoylated, this mutation should not have any effect on membrane binding. The 
corresponding mutation in HIV-1 however, should knock out myristoylation and 
therefore decrease membrane binding. My results showed that against 70%POPC: 
30%POPS liposomes, EIAV G2A binding decreased from ~26% to ~21%, and from 
~36% to ~24% against 34%POPC: 30%POPS: 36%Chol liposome binding when 
compared to EIAV WT (Fig. 2B). As expected (37, 38, 39), I saw a drop by 15% in 
HIV-1 G2A Gag binding against 70%POPC: 30%POPS liposomes and a drop by 30% 
in membrane binding with 34%POPC: 30%POPS: 36%Chol liposomes (Fig. 2C).  
The second set of mutations was an EIAV D3A Gag mutation and the converse 
mutation HIV-1 A3D Gag, (Fig. 2A). It has been shown that Asp at the 3rd position 
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can inhibit myristoylation by causing a shift to N-acetylation (21).  I therefore 
hypothesized that the EIAV D3A Gag mutation would be myristoylated, while the 
corresponding HIV-1 A3D mutation would inhibit N-myristoylation. While EIAV D3A 
Gag only showed a very small decrease in binding to 70%POPC: 30%POPS (~2%), 
and 34%POPC: 30%POPS: 36%Chol (~5%) (Fig. 2B), HIV-1 A3D binding decreased 
by ~5% to 70%POPC: 30%POPS liposomes, and by ~20% to 34%POPC: 30%POPS: 
36%Chol liposomes (Fig. 2C).   
The third mutant I cloned was EIAV P4A Gag (Fig. 2A). Utsumi et al. found 
that amino acids with radii of gyration over 1.80 A, such as Proline, could inhibit N-
myristoylation (21). This phenomenon has also been shown independently in plants 
(40). I hypothesized that the presence of the Pro in EIAV at position 4 may play a 
similar inhibitory role N-myristoylation. However, again I saw comparable 
membrane binding with EIAV WT Gag: EIAV P4A Gag bound at ~25% to 70%POPC: 
30%POPS liposomes, and at ~35% to 34%POPC: 30%POPS: 36%Chol liposomes 
(Fig. 2B).  
Finally, I cloned an EIAV D3A P4R Gag double mutant (Fig. 2A). This mutation 
replaces the first four amino acids of EIAV MA with HIV-1 MA. I planned to use this 
construct to investigate whether downstream residues further in EIAV MA may be 
inhibiting N-myristoylation of EIAV MA. I plan to conduct liposome flotation 
reactions with this construct in the near future.  
 From these liposome flotation assays, I have found that changes in the first 
four amino acids of EIAV MA had no significant effect on membrane binding of EIAV 
Gag. Because each mutation slightly decreased EIAV Gag association with liposomes, 
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I inferred that these mutations did not induce myristoylation of EIAV Gag. These 
results also been confirmed by preliminary 3H-myristic acid radiolabeling of EIAV 
WT Gag and mutants (data not shown). Though these mutations did not significantly 
affect EIAV Gag association, my results indicate that HIV-1 Gag binding is sensitive 
to mutations at the 2nd and 3rd residue position. HIV-1 G2A and A3D Gag mutations 
had a larger effect on HIV-1 Gag binding to 34%POPC: 30%POPS: 36%Chol 
liposomes, decreasing binding by about ~20%.  These results not only confirm that 
G2A is indeed non-myristoylated, but also that the A3D mutation in HIV-1 MA may 
inhibit myristoylation.  
 
EIAV Gag-GFP mutants have no significant effect in vivo on virus release 
 
To investigate the effect of the EIAV Gag mutants in vivo, I re-cloned my EIAV 
and HIV-1 Gag liposome flotation constructs (Fig. 2A) into a pEGFP-N1 vector and 
transfected 293T cells. Consistent with the liposome binding assay results, I found 
no significant change in virus release of EIAV-Gag-GFP mutants from 293T cells. 
Virus release was measured by western blot comparison of VLP-associated Gag in 
the medium with the total Gag 24 h post-transfection. A representative Western Blot 
with cropped EIAV Gag-GFP and HIV Gag-GFP bands is shown in Figure 3A. EIAV 
G2A, EIAV D3A, and the double mutant EIAV D3A P4R Gag-GFP showed a slight 
decrease in virus release (~15%) while EIAV P4A Gag-GFP showed a slight ~15% 
increase in VLP release (Fig. 3B). However, no VLP release was seen in 
corresponding HIV-1 G2A Gag-GFP or HIV-1 A3D Gag-GFP mutants (Fig. 3B). While 
the identities of the HIV-1 bands were clear, there was some ambiguity about the 
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EIAV Gag-GFP bands due to cleavage products and unfamiliarity with viral banding 
patterns. In summary, I concluded that while my EIAV Gag mutants did not cause 
significant decreases in membrane binding, overall these mutations—with the 
exception of EIAV P4A Gag-GFP—did decrease virus release by ~15%. Interestingly, 
EIAV P4A Gag-GFP increased virus release by ~15%. In addition, virus release of 
HIV-1 was completely abolished in HIV-1 G2A and HIV A3D Gag-GFP mutants, 
therefore underlining HIV-1’s dependence on myristoylation for virus release (39, 
41).  
 
EIAV Gag-GFP mutants do not show aberrant localization in 293T cells 
To visualize the localization of EIAV Gag-GFP in vivo, I transfected 293T cells 
and imaged them using confocal microscopy 24h post-transfection. EIAV WT Gag-
GFP localized to the plasma membrane and had puncta, showing VLP formation and 
release (Fig. 4A). A similar phenotype (Fig. 4B) was seen with EIAV G2A-Gag GFP 
and is consistent with in vitro membrane binding (Fig. 2B) and virus release 
measurements (Fig. 4B). In Fig. 4B, I also see EIAV association with endosomal 
compartments that has previously been reported by Fernandes et al. to be 
important for EIAV Gag processing (7).  
HIV-1 Gag-GFP mutant transfections were carried out in parallel. As 
expected, HIV WT-GFP localized primarily to the plasma membrane and showed a 
punctate distribution, indicating virus assembly (Fig. 4C). HIV-Gag-A3D-GFP, 
however, showed an abnormal phenotype, localizing in clusters throughout the cell 
(Fig. 4D). Though confocal microscopy of HIV Gag-G2A-GFP has not yet been 
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performed, previous studies using electron microscopy have shown that 
myristoylation deficient HIV-1 Gag molecules undergo intracellular assembly (32, 
42), forming virus particles without membranes. Two-photon laser scanning 
microscopy of HIV-1 GagMBD in DF-1 cells showed a similar distribution, therefore 
showing that the inhibition or decrease of membrane association causes aberrant 
distribution in cells (43). Furthermore, this same study showed that Gag-Gag 
interactions are not abolished in HIV-1 GagMBD mutants; this indicates that 
concentration dependent interactions of Gag in the cytoplasm are in fact sufficient 
for the intracellular assembly of virus particles (43).  In summary, my fluorescence 
imaging studies of EIAV Gag-GFP WT and EIAV Gag-G2A-GFP have confirmed my in 
vitro liposome flotation and virus release analyses. HIV-1 A3D Gag-GFP also forms 
intracellular clusters which I have interpreted to be the indicative intracellular 
assembly of virus particles.  
 
 
DISCUSSION 
 
 In this study, I addressed two main questions. First, what are the lipid 
signatures that drive EIAV Gag membrane association? With liposome flotation 
assay comparisons between HIV-1 and RSV, I have found that EIAV Gag membrane-
association is driven by some of the same factors; in particular, EIAV Gag is sensitive 
to an acidic lipid environment and cholesterol containing membranes. This has two 
implications: first, like other retroviral Gags, EIAV Gag association with the PM 
seems to be primarily driven by electrostatic interactions. These results have been 
independently corroborated by computational models of EIAV MA (4), the published 
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crystal structure of EIAV MA (30), and fluorescence anisotropy liposome binding 
experiments with EIAV MA (31). Taken together, these results highlight the 
importance of the EIAV MA basic surface patch. Thus, using the in vitro liposome 
binding system, I have confirmed these previous models of EIAV MA binding by 
showing that full length EIAV Gag behaves similarly.  
Second, my results suggest—albeit indirectly—that EIAV Gag may also bud 
from lipid raft microdomains. As seen with HIV-1 and RSV Gag, EIAV Gag sees an 
>10% increase in binding to liposomes with the addition of cholesterol, confirming 
Dick et al.’s conclusion that no fatty acid modification (ie myristoylation) is needed 
for the sensing and response to increased cholesterol concentrations (18). At the 
same time, Dick et al’s results have highlighted the complexity of the retroviral 
response to cholesterol-containing membranes, suggesting that Gag is not just 
simply recognizing areas of higher lipid order (18). Rather, the addition of 
cholesterol seems to increase lipid packing, which makes more PS or PI(4,5)P2 
available for Gag-interactions (18). To investigate further, a more informative 
systematic study of EIAV Gag binding to high melting temperature (Tm) lipids such 
as SM, distearoyl phosphatidylcholine (DSPC) and to low melting Tm-lipids such as 
dioleoyl phosphatidylcholine (DOPC) would elaborate EIAV Gag’s membrane 
binding capabilities, and whether it, like other retroviral Gags, can also sense the 
acyl chain environment (18).  
The second main question of my thesis research was, why is EIAV Gag not N-
myristoylated? Though EIAV Gag has the commonly accepted consensus sequence 
for myristoylation, M-G-X-X-X-S/T-X-X, (21, 22, 23, 24), it is widely accepted to lack 
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a myristoyl group 2 (8,29). To study this phenomenon, I used results by Utsumi et al. 
( 21) as a basis to investigate whether Asp and Pro residues at the third and fourth 
position of EIAV MA inhibit myristoylation. Preliminary 3H-myristic acid 
radiolableled expression in an in vitro rabbit reticulocyte system has confirmed 
previous HPLC-purification of EIAV Gag (28,29), which have reported that EIAV WT 
Gag is indeed, not myristoylated. This result was also confirmed by the EIAV G2A 
mutant which caused no significant decrease in binding to 70%POPC: 30%POPS and 
34%POPC:30%POPS:36% Chol liposomes. Furthermore, I saw no decrease in 
membrane binding with EIAV D3A, or EIAV P4A Gag mutants. . That these mutants 
are not able to induce the addition of a myristoyl group suggest not only that the 
permissiveness of the consensus sequence of myristoylation may need to adjusted 
at these positions, but also that further downstream residues may be inhibiting 
myristoylation, and therefore, that the structure of EIAV MA may simply not be 
permissive to myristoylation.  
 However, these mutants consistently showed a slight decrease in membrane 
binding that was mirrored by a ~15% decrease in VLP production as measured by 
western blot with transfected 293T cells. Though these mutants may not be able to 
shift EIAV Gag myristoylation, they may in fact be important in EIAV Gag-membrane 
targeting. Interestingly, the EIAV P4A Gag mutant, which showed the least decrease 
in membrane binding, resulted in an increase in VLP production by 15% when 
compared to EIAV WT Gag. What complicates this phenomenon even further is that 
the EIAV D3A P4R double mutant did not exhibit the same increase in VLP 
production.  
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Though the explanation for this phenomenon remains opaque, I offer the 
following hypothesis. Sequence alignment of EIAV MA with HIV-1 MA by Hatanaka 
et al. showed that helix 1 (H1) of EIAV MA begins with a Thr-6, and continues until 
Val-18. The same helix in HIV-1 begins with a Leu-8 and ends with an Ile-19. Based 
on the crystal structure of EIAV MA and computational modeling, Hatanaka et al. 
have suggested that the amphipathic H1 in EIAV MA may insert itself into the head 
group region of the lipid bilayer, therefore serving as a protein-mediated 
replacement for the myristoyl anchor in HIV-1 (30). Because a Ser or Thr residue is 
absolutely necessary for N-myristoylation (21), I hypothesize that the participation 
of EIAV MA’s Thr-6 in a helical structure may in fact mask NMT from recognizing the 
presence of this important residue. Furthermore, I posit that the P4A mutation may 
permit the extension of H1 to residue 4. While this may not enhance transient 
membrane binding to liposomes, I predict that such a mutation and extension of H1 
may anchor EIAV Gag more securely once it is present at the membrane. Therefore, I 
believe that the model put forth by Hatanaka et al. is correct (30). According to this 
model, EIAV Gag, like RSV Gag, is driven to the PM by the electrostatic attractions 
between its basic surface patch and the acidic lipid environment of the inner leaflet. 
Once near the membrane, amphipathic H1 inserts into the PM, securing EIAV MA 
into the membrane. This model is similar to the “myristoyl-switch” model for HIV-1 
Gag binding. Under this model, HIV-1 is driven in part to the PM by electrostatic 
interactions; specific binding to PI(4,5)P2 acts as an allosteric trigger that causes a 
change in MA conformation (13, 41). This shift in MA conformation exposes the N-
terminal myristate for insertion into the PM (13, 41). Thus, my EIAV P4A mutant 
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may be extending a similar insertion into the membrane by elongating H1 and 
therefore causing a small increase in the stable anchoring of EIAV MA. Such an 
interaction may enhance EIAV Gag’s targeting to membrane rafts, or enhance 
concentration-dependent accumulation of EIAV Gag to the PM for VLP assembly and 
release (41, 43). Since no corresponding increase in VLP production was seen in the 
EIAV D3A P4R double mutant, the replacement of Pro with Arg may disrupt H1’s 
amphipathicity and therefore, is not a permissive residue for H1 incorporation.  
  Interestingly, I found that the HIV-1 A3D mutation did cause a decrease in 
both in vitro liposome binding and an abolishment of virus release from 293T cells. 
This is the first time that such a mutation has been made in HIV-1 MA and has 
showed a dramatic effect on HIV-1 assembly. Such a phenomenon has two 
implications. First, the addition of an Asp residue at residue 3 can in fact inhibit 
myristoylation (21). Second, the myristoylation of HIV-1 Gag is necessary for VLP 
release. This is confirmed not only by my own HIV-1 G2A Gag results, but also in 
previous studies which showed that the knockout of myristoylation abolishes VLP 
release and leads to aberrant intracellular VLP formation in the cytoplasm (32). 
Therefore, the HIV A3D mutant shows that though HIV-1 Gag is able to associate 
transiently with membranes independently of its myristate moiety, the 
concentration dependent accumulation of Gag or association with membrane rafts 
for proper assembly is contingent on the sustained anchoring of Gag at the 
membrane by myristate (32, 41, 44).  
There are a number of avenues to explore for future work on this project. 
First, a continuation of membrane binding comparisons of EIAV with HIV-1 and RSV 
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against a liposome panel of 100%POPC, 68%POPC: 30%POPS: 2%PI(4,5)P2, and 
40%POPC:60%POPS liposomes will be important to more broadly determine EIAV 
Gag’s plasma membrane binding requirements. Because EIAV MA has been reported 
to have hydrophobic binding characteristics, I predict that EIAV Gag, but not HIV-1 
or RSV, to bind at low levels to electrically neutral 100%POPC liposomes (30). 
Second, since EIAV Gag lacks a PI(4,5)P2 binding pocket (30), I hypothesize that 
while binding to 68%POPC: 30%POPS: 2%PI(4,5)P2 may increase, this interaction is 
purely due to electrostatics, and therefore EIAV Gag membrane association is not 
dependent on PI(4,5)P2. This work will also need to be corroborated with in vivo 
studies using previously established methods such as phosphatase treatment to 
isolate the effects of PIP species abolishment on EIAV virus release(3). Third, testing 
against 40%POPC: 60%POPS liposomes may provide further corroboration of EIAV 
Gag’s dependence on electrostatic interactions to get to the PM. All work should also 
include testing of the EIAV D3A P4R Gag double mutant binding to liposomes. 
Fourth, virus release western blots should be repeated with EIAV and HIV-1 Gag 
specific antibodies. The western blots currently used in this study were subject to 
some ambiguity due to unfamiliarity with EIAV Gag banding patterns and cleavage 
products. Repeating these results with a specific EIAV antibody will clarify the 
identity of the bands seen and reduce the non-specific binding seen using anti-GFP 
antibodies. Additional cell types should also be used to confirm results and isolate 
cell-type specific variation. Finally, I hope to use confocal microscopy to continue to 
look at EIAV and HIV-1 mutant localization in 293T cells.  
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Additionally, I propose three long-term goals. First, to continue with 3H-
myristic acid radiolabeled expression tests to confirm my EIAV MA mutant 
hypotheses. Second, purifying EIAV MA and using the same systematic membrane 
binding comparison with HIV-1 MA and RSV MA to isolate EIAV MA’s interactions 
with the PM. Third, to do reciprocallly replace HIV-1 MA’s H1 with EIAV MA’s H1 to 
test my proposed model of EIAV Gag’s MA H1 role in myristoylation inhibition.  
In conclusion, I have shown that EIAV Gag is dependent on electrostatics for 
membrane binding. EIAV Gag also prefers cholesterol-containing membranes which 
may underlie a preference or dependence on budding from lipid raft microdomains. 
I have also shown that EIAV Gag is indeed not myristoyalted and have constructed a 
series of EIAV and HIV-1 MA mutations that have reaffirmed HIV-1’s dependence on 
myristoylation for PM localization and virus release. Of these, the HIV-1 A3D mutant 
showed a dramatic effect on HIV-1 Gag localization to the plasma membrane, and 
decreased virus release. Confocal microscopy of this mutant also revealed 
intracellular assembly of virus particles that mirror previous microscopy results 
with HIV-1 G2A and HIV-1 GagMBD. My EIAV mutants have also led me to 
hypothesize that EIAV Gag is not myristoylated due to the sequestering of Thr at 
position 6 in H1 of EIAV MA.   
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APPENDIX I 
 
INTRODUCTION 
 
 Protein-lipid interactions are essential for normal cellular activities such as 
signal transduction and transport. However, research in this field has been limited 
by the development of accurate, reproducible biochemical tests that replicate 
relevant physiological constraints (45). Current methods include surface Plasmon 
Resonance (SPR), spectroscopic methods such as fluorescence or Nuclear Magnetic 
Resonance (NMR), microscopy, and in vitro liposome flotation assays (45, 46). 
These methods however, are often time-consuming, require the use of complex 
equipment, and need extensive training for data interpretation. Hence, a part of my 
thesis research was dedicated to the development of an alternative membrane-
binding assay using silica beads to meet the demand for a simple, quick method to 
measure protein-lipid binding.    
 In the Vogt lab, we are concerned with protein-lipid interactions in the 
context of retroviral assembly. More specifically, the big picture application of this 
alternative assay was to develop a more efficient way to study the lipid signatures 
that drive Gag’s recognition, localization, and accumulation at the plasma 
membrane. Traditionally, these studies have primarily been performed with 
liposome flotation assays (3, 14, 15, 18). Liposomes with the lipid compositions of 
interest are incubated with protein, layered in a sucrose gradient, and spun at high 
speed to separate membrane bound and non-membrane fractions. The fractions are 
then run on SDS-PAGE, and analyzed by Coomassie staining or autoradiogram.   
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 My proposed membrane-binding assay uses high performance liquid 
chromatography (HPLC) silica beads (diameter=3 m) which are coated with C18 
hydrocarbon chains that seed the formation of a lipid monolayer. This assay is much 
simpler and less time consuming than the standard liposome flotation assays used 
by the Vogt Lab; testing simply requires the incubation of lipid-coated beads with 
protein and micro-centrifugation at 5,000 rpm for 60 s to pellet the beads. No 
sucrose gradient is needed to separate membrane bound from non-membrane 
bound protein. Membrane bound protein pellets with beads during centrifugation; 
non-membrane protein remains in the supernatant. After SDS-PAGE, the amount of 
lipid-associated protein is then calculated as a ratio of pelleted, bead-associated 
protein to total protein loaded.  
 Previous studies have utilized these silica beads in a variety of ways to study 
protein-lipid interactions. In 2008, Yeung et al. described the use of a similar system 
to study the specificity of a PS probe—Lactahedrin C2. (Lact-C2) Yeung et al. 
measured the displacement of Lact-C2 upon the addition of PS-containing liposomes 
to show Lact-C2 specificity for PS (1). More recently, Alfadhi et al. (47) described the 
coating of silica beads with HIV-1 MA, incubation with fluorescently tagged 
liposomes, and measurement of bead-lipid fluorescence to determine HIV-MA 
phospholipid headgroup preferences.  VanderVen et al. have also shown the utility 
of such a system for high-throughput small molecule discovery for compounds that 
disrupt phagosomal maturation (87). This method also depended on fluorescence 
measurements: fluorogenic lipid coated beads were overlaid onto a macrophage 
monolayer and analyzed by a fluorescent plate reader (48). What makes my 
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proposed system unique, however, is that it measures direct interaction of the 
protein with the lipid monolayer of the bead itself. While this technique can be used 
with fluorescent proteins as well, this alternative bead-binding assay is also 
amenable for analysis by SDS-PAGE for proteins without fluorescent tags.  
 To determine the potential of this assay for future studies of protein-lipid 
interactions, I purified eGFP-LactC2, the specific PS sensor advertised by Yeung et al 
(1, 49), and compared binding to 100% phosphatdiylcholine (PC) and 10%PS lipid 
coated beads with liposomes of the same compositions. I hoped to demonstrate 
comparable membrane-binding results to currently used technology to illustrate the 
usefulness of such an assay. I also investigated the effects of electrostatics and bead-
surface blockers on protein-binding to the beads.  
 
MATERIALS AND METHODS 
Protein Purification 
 ppSUMO-eGFP-LactC2 was generously provided by Rob Dick (Cornell 
University) for this study. This construct was transformed into BL21 DE3/pLysS 
E.coli cells for increased protein yield. Overnight cultures of BL21 cells were grown 
in Lysogeny Broth (LB) with kanamycin at 37C. Overnight cultures were diluted 
1:100 in fresh medium and grown at 37C to an optical density of 0.5 at 600 nm. 
Cultures were then induced with 0.5 mM isopropyl--D-thiogalactopyranoside 
(IPTG) and grown for four hours at 30C.  Cultures were pelleted and frozen at -
20C.  
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 The frozen cell pellet were resuspended in lysis buffer (20 mM Tris-HCl, 500 
mM NaCl, 1 mM phenylmethanesulfonylfluoride (PMSF). Cells were lysed by 
sonication and centrifuged at 90,000 rpm in a TLA-110 rotor (Beckman) at 4C for 
1h. 1 mL of supernatant was aliquoted and flash frozen for cell-extract surface 
blocking experiments. The rest of the supernatant was loaded onto a nickel affinity 
chromatography column (QIAGEN) and incubated for 2h at 4C. The column was 
washed four times with 5 mL of wash buffer (20 mL of 20 mM Tris-HCl, 500 mM 
NaCl, 20 mM imidazole) before eluting with 10 mL of elution buffer (20 mM Tris-
HCl, 500 mM NaCl, 200 mM imidazole). Fractions were analyzed by SDS-PAGE; 
SUMO-eGFP-LactC2 containing fractions were dialyzed overnight at 4C in Dialysis 
buffer (20 mM Tris-HCl, 500 mM NaCl, pH 7) and supplemented with previously 
purified Ubl-specific protease 1 (ULP). ULP protease is highly specific for the SUMO 
protein and used to cleave SUMO from eGFP-LactC2. Dialyzed fractions were loaded 
onto a nickel affinity chromatography column (QIAGEN) and incubated for 2h at 4C. 
Column was washed twice with 5 mL of 20 mM Tris-Hcl, 500 mM NaCl, pH 7. eGFP-
LactC2 was eluted twice with 5 mL of wash buffer. 5 mL of elution buffer was added 
to elute off ULP protease. Fractions were analyzed by Coomassie-Blue stained SDS-
PAGE. Protein containing fractions were concentrated to approximately 15 mg/mL 
with an Ambicon (Millipore) tube. Protein was flash frozen in an Ethanol-Dry Ice 
bath and stored at -80C in 20% glycerol and 10 mM dithiothreitol (DTT). Protein 
purification gels can be seen in Appendix Fig. 1.  
 
Preparation of lipid-coated silica beads 
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Silica Nucleosil C18 reverse phase HPLC beads (diameter= 3 m) were 
coated with lipids as previously described (47) with modifications. 20 mg of beads 
were dissolved in 2 mL of chloroform and stored at 4C. To make 100% PC beads, 
0.231 mg of egg-PC (Avanti) in chloroform was added to 200 L of beads. To make 
90%PC: 10%PS beads, 0.208 mg of egg-PC and 0.025 mg brain-PS (Avanti) were 
added to 200 L of beads. Approximately 100x more lipid was added than needed to 
ensure complete coverage of bead surfaces. Beads and lipid solution were dried 
down with N2 gas. 200 L bead preparation buffer (20 mM HEPES, 100 mM NaCl, pH 
7) was added to dried beads and sonicated in a water bath while pipetting up and 
down to resuspend beads. Lipid coated beats were washed with 200 L of bead 
preparation buffer by vortexing and centrifugation at 5,000 rpm for 1 min three 
times. Beads were stored in 200 L of bead preparation buffer at a final 
concentration of 100 mg/mL at 4C before use.  
 
Silica bead binding Assay 
Approximately 3 g of eGFP-LactC2 was added to 1 mg of beads. Each protein 
aliquot was spun at 14,000 rpm for 10 min at 4C to pellet any aggregated protein. 
Mixtures were incubated on ice for 10 minutes. Beads were washed twice with 100 
L buffer by pipetting up and down and centrifuged at 5,000 rpm for 5 min to pellet 
beads and protein. All buffers used were 20 mM HEPES at final NaCl concentrations 
of 100, 300, or 500 mM NaCl. NaCl concentrations were varied to assess the effects 
of electrostatics on eGFP-LactC2 binding to the lipid-coated beads. After 2nd wash, 
beads were resuspended in 30 L of buffer and centrifuged at 5,000 rpm for 5 mins. 
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Supernatant, 30 L from each wash, and beads were run on SDS-PAGE. Gels were 
analyzed after Coomassie staining by measuring dividing of protein in bead fraction 
by total protein loaded. All quantification was performed in ImageQuant software.  
Bead surface blocking experiments were carried out with either addition of 
SUMO-eGFP LactC2 purification cell extract or with Bovine Serum Albumin (NEB). 
Cell extract aliquots were spun at 14,000 rpm for 10 min at 4C to spin down any 
aggregates. 10 L of cell extract was incubated with beads and proteins on ice for 10 
mins. Similarly, 0.01 mg of BSA was added during incubation to block bead surface 
from non-specific binding.  NaCl concentrations of buffers were altered to maintain 
100, 300, or 500 mM NaCl balance.  
 
Liposome Preparation 
Liposomes were prepared using rapid solvent exchange as described (18, 
33).  Chloroform solutions of purified L--phosphatidylcholine (Egg, Chicken) 
[Avanti] and L--phosphatidylserine (Brain, Porcine) [Avanti] were mixed to make 
100%PC and 90%PC: 10%PS liposomes. 20 mM HEPES, pH 7.0 buffer was added to 
the lipid solutions in glass tubes, vortexed under vacuum for 90 seconds, and sealed 
under Argon gas to yield large unilamellear vesicle (LUV) solutions at 10 mg/mL. 
Hydrated liposomes were extruded in a mini-extruder block (Avanti) for no less 
than 60 times through 100-nm-polycarbonate filters (Avanti) to homogenize 
liposome species. All liposomes were stored at 4C and used within 2 weeks.  
 
Liposome Binding Assay 
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Liposome binding assays were conducted as previously described (18). 5 g 
of eGFP-LactC2 was incubated with 15 L binding buffer (20 mM HEPES, pH 7.0) 
and 50 g of LUVs at room temperature for 10 min. Incubation was performed at 
either 160 (physiological) or 300 mM NaCl. 80 L of a 67% wt/wt sucrose (20 mM 
HEPES, pH 7.0) solution was then mixed with each binding reaction. 80 L of this 
mix was then placed in a TLA-100 ultracentrifuge tube (Beckman), and layered with 
120 L 40% wt/wt sucrose (20 mM HEPES, pH 7.0), and 40 L 4% wt/wt sucrose 
(20 mM HEPES, pH 7.0) solutions.  Binding mixtures were centrifuged at 90,000 rpm 
in a TLA-100 rotor (Beckman) for 1 h. Four 60-L fractions were collected from 
each reaction and resolved by SDS-PAGE. Gels were Coomassie stained and analyzed 
with ImageQuant software. The first two fractions represented liposome-bound Gag 
while the bottom two fractions represented non-liposome bound Gag. Results were 
averaged and graphed using Prism5 (GraphPad Software). Error bars represent 
standard deviations from the mean. No less than three independent experiments 
were conducted for each construct and lipid type. 
 
RESULTS 
Purification of eGFP-LactC2 
Appendix Fig. 1 shows an example of an eGFP-LactC2 purification. Protein 
was expressed using a ppSUMO backbone in BL21-DE3/pLysS E.coli cells. SUMO-
eGFP LactC2 can be seen at ~67 kDa in Appendix Fig. 1A. ULP protease was used to 
cut off SUMO tag to yield eGFP-LactC2, ~45 kDa (Appendix Fig. 1A-B). SUMO Tag 
(~12 kDa) and ULP Protease (~26 kDa) can be seen in Appendix Fig. 1B, lane 5. 
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Purified protein was concentrated using Ambicon (Millipore) filter and stored in 
20% glycerol with 10 mM DTT. Protein was stored at -80C until use.  
 
eGFP-LactC2 binds similarly to Silica Beads and Liposomes 
 
To assess the utility of  my silica bead binding assay, I compared eGFP-LactC2 
binding to both 100%PC and 90%PC:10%PS beads and liposomes. In Appendix Fig. 
2A, supernatant, wash, and bead fractions were loaded onto SDS-PAGE. Consistenly, 
a non-significant amount of eGFP-Lactc2 was eluted from beads during washes, 
suggesting a stable interactions with lipids on beads. eGFP-LactC2 showed ~30% 
binding to 100%PC beads and ~40% binding to 90%PC:10%PS beads. Because 
eGFP-LactC2 has been previously reported by Yeung et al. to show no relative 
binding to PC beads (1), I hypothesized that binding to PC-silica beads was due to 
non-specific binding to uncoated silica bead surfaces. To assess whether increasing 
NaCl concentrations could cause eGFP-LactC2 to bind more discriminately, I 
conducted binding experiments with increasing NaCl concentrations (Appendix Fig. 
2B-2C). Appendix Fig. 2B is a representative example of a eGFP-LactC2 binding to 
100%PC and 90%PC:10%PS silica beads at 100, 300, and 500 mM NaCl. I found that 
while eGFP-LactC2 binding to 100%PC decreased slightly with increasing NaCl 
concentration, there was no significant decrease in binding to 90%PC:10%PS beads.  
In Fig. 2D, I show an example of a purified eGFP-LactC2 binding experiment 
to 100%PC liposomes at 160 mM and 300 mM NaCl. Because eGFP-LactC2 was 
stored at 500 mM NaCl, 100 mM NaCl binding experiments were not performed 
because of volume restrictions of the liposome flotation assay. Similarly, in 
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Appendix Fig. 2E,  I show an example of an eGFP-LactC2 binding experiment to 
90%PC:10%PS liposomes at 160 and 300 mM NaCl. I found that eGFP-LactC2 
showed comparable binding to silica beads at 100 mM NaCl, and to 100%PC 
liposomes at 160 mM NaCl (Fig. 1F). As with binding to silica beads, I saw 5% 
decrease in eGFP-LactC2 binding to 100%PC liposomes at 300 mM NaCl. 
Furthermore, I saw similar binding results, ~30% binding to 90%PC:10%PS beads 
at both salt concentrations.   
From these results, I concluded that eGFP-LactC2 binds similarly to both 
silica beads and liposomes of the same compositions. Furthermore, I concluded that 
eGFP-LactC2 specificity is dependent on electrostatics. However, in contrast to 
previously reported results by Yeung et al., eGFP-LactC2 also seems to have 
hydrophobic binding capability to electrically neutral membranes. To corroborate 
my results, I conducted a series of bead-surface blocking experiments to isolate non-
specific binding of eGFP-LactC2 to the silica bead from its promiscuity to binding 
electrically neutral membranes.   
 
Non-specific binding of eGFP-LactC2 to silica bead surface is reduced by 
addition of BSA or Cell Extract 
In Appendix Fig. 3, I compared the effects of eGFP-LactC2 binding to 100%PC 
and 90%PC:10%PS silica beads with two blocking agents: BSA and cell extract. 
Appendix Fig. 3A is a representative SDS-PAGE of a binding experiment with BSA. 
The lower band, at approximately 45 kDa is eGFP-LactC2 while the upper band, at 
65 kDa is BSA. Fig. 3B is a representative SDS-PAGE of a binding experiment with 
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cell extract. Cell extract was prepared after sonication and centrifugation of cell 
pellets during eGFP-LactC2 protein purification. CE was flash frozen, and spun down 
at 14,000 rpm for 10 min at 4C to spin down any aggregated protein. I 
hypothesized that the addition of cell extract would supplement the binding mixture 
with proteins that would bind to uncoated bead surfaces to block non-specific 
binding of eGFP-LactC2. The lower band at 45 kDa is eGFP-LactC2 while the 
prominent upper band at ~67 kDa is SUMO-eGFP-LactC2. With BSA, eGFP-LactC2 
consistently bound at ~20% to 100%PC silica beads (Appendix Fig.3C). 
Furthermore, adding BSA as a surface blocker did not cause a decrease in eGFP-
LactC2 binding with increasing NaCl concentrations. eGFP-LactC2 bound at similar 
levels to BSA-free 90%PC:10%PS silica beads, ~45% at all NaCl concentrations. 
Panel 3D shows quantification of eGFP-LactC2 binding with cell extract as a blocking 
agent. Binding was similar to BSA-blocked binding: eGFP-LactC2 bound at a 
consistent ~20% to 100%PC silica beads, and at ~35% to 90%PC:10%PS beads. 
There was no decrease in eGFP-LactC2 binding to cell-extract blocked 100%PC 
beads with increasing NaCl but eGFP-LactC2 binding to CE-blocked beads showed 
much greater heterogeneity. 
 Appendix Fig. 3 shows that blocking with either BSA or CE does indeed 
prevent some non-specific binding to the non-lipid coated bead surfaces. Because 
BSA blocked beads showed more consistent binding reuslts, it may be a better 
candidate for surface blocking than cell extract. In contrast to previously published 
results, I concluded that eGFP-LactC2 does indeed bind at ~20% to electrically 
neutral membranes. A comparison of Appendix Fig. 2 and Appendix Fig. 3 suggests 
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that approximately 10% of eGFP-LactC2 binding to unblocked 100%PC silica beads 
was due to non-specific binding to the bead surface. While electrostatics caused 
non-specific binding to decrease in the absence of a blocking agent, increasing salt 
concentrations did not cause a significant change to eGFP-LactC2 binding to 
100%PC beads. Together, these results demonstrate that eGFP-LactC2 binding to 
electrically neutral membranes is a specific interaction and not dependent on 
electrostatic interactions.  
 
DISCUSSION 
 I began an investigation into the potential of using lipid coated 3 m 
diameter HPLC silica beads as an alternative membrane binding platform for 
studying protein-lipid interactions. BecauseLactC2, the C2 domain of the 
Lactahedrin protein, has been previously been reported by Yeung et al. to be a very 
specific PS sensor (1), I decided to purify eGFP-LactC2 to undergo some control 
binding experiments to determine the utility of this assay. In contrast to Yeung et 
al.’s results, I found that eGFP-LactC2 binds at ~20% to 100%PC membranes, 
therefore showing that eGFP-LactC2 is not nearly as specific as previously 
advertised (1). These results were confirmed by purified eGFP-LactC2 flotations 
with 100%PC liposomes and by in vitro rabbit reticulocyte translated eGFP-LactC2 
flotations (Katherine Konvinse [Cornell University]- unpublished results).  A crystal 
structure of LactC2 revealed 2 hydrophobic spikes that are predicted to insert 
themselves into membranes (50), which may explain eGFP-LactC2’s binding to 
electrically neutral membranes. At the same time, I did find that eGFP-LactC2 
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increases by 10-20% with the addition of 10%PS; this suggests that eGFP-LactC2 is 
indeed senstive to PS, but that this membrane association may be contingent on, or 
greatly enhanced by anchoring in electrically neutral lipid environments.  
 Though 100x more lipid was added than needed to coat bead surfaces, I 
showed that binding of eGFP-LactC2 to 100%PC beads varied in the presence 
surface blocking agents, therefore demonstrating that some non-specific binding to 
the silica bead surface occurs. I used two different blocking strategies, BSA and cell 
extract, and showed that both strategies yielded similar membrane binding results.  
However, the addition of BSA results in less variation which may make it the better 
blocking agent for future studies. Moreover, adding surface blocking agents to 
binding reactions stabilized specific binding in increasing NaCl concentrations. 
These results show that these beads can be used to achieve stable, consistent 
binding at a physiological, ~160 mM NaCl, salt concentration.  
 Though these results are a promising start for future work on this assay,  a 
number of problems and limitations remain. First, bead coating should be attempted 
with fluorescent lipid probe mixtures to evaluate coating on the bead surface. This 
will also determine whether irregular lipid distributions form on the bead surface 
that may affect protein-lipid interactions. Second, binding experiments of known 
proteins with known behavior should be conducted and compared with liposome 
flotation results. Third, more complex lipid mixtures should be coated onto bead 
surfaces to measure protein binding to more physiologically relevant lipid 
environments. This may include the addition of cholesterol, charged PIP species, or 
lipids of varying saturation and may increase the uses of this assay in protein 
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binding response to parameters such as lipid order. I have previously attempted to 
make beads with higher PS concentrations (>30%PS) but found that coating was 
less efficient, perhaps due to electrostatic repulsion. Electrostatic repulsion between 
beads also seemed to prevent efficient pelleting in microcentrifuge tubes. Binding 
with silica beads with higher PS concentrations gave varied, inconsistent results 
(data not shown). These results suggest coating with charged lipids may result in 
irregular distributions on the bead surface and therefore, different concentrations of 
lipid coating on the surface than expected. Furthermore, inefficient pelleting of 
beads may have also resulted in changes in the amount of beads present in each 
binding reaction. Hence, further modifications of bead preparation buffer, such as 
increasing ionic strength, may alleviate some of these issues.  
 In conclusion, I have shown that this silica bead binding assay may be a new 
and more efficient way to study protein-lipid interactions. My results showed that 
though eGFP-LactC2 is indeed sensitive to PS, it also binds to 100%PC Silica beads 
and 100%PC liposomes. These results, along with unpublished data by Katherine 
Konvinse (Cornell University), have shown that previous reports of LactC2 
specificity may be incorrect. I also conducted testing on the effects of bead surface 
blocking agents on eGFP-LactC2 binding and found that the addition of BSA not only 
reduced non-specific binding, but also resulted in more consistent binding in my 
assay. Future testing should be conducted with different proteins of known behavior 
and lipid compositions to expand the utility of this assay to future protein-lipid 
interaction studies.  
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FIGURE LEGENDS 
 
FIG.1 Liposome binding assay comparison of EIAV Gag with HIV-1 and RSV Gag.  
(A) Example of HIV-1, RSV, EIAV Gag flotation autoradiograms against two liposome 
compositions. Top two fractions were interpreted as membrane bound (MB) while 
bottom two fractions were non-membrane bound (NMB). Amount of binding was 
calculated by dividing MB Gag by total Gag. (B) Average binding against 
70%POPC:30%POPS and 34%POPC:30%POPS:36%Chol liposomes. Quantification 
was performed of no less than three flotation reactions for each composition. Error 
bars represent standard deviations from the mean.  
 
FIG.2 Liposome binding assay comparison of EIAV and HIV-1 mutants against 
70%POPC:30%POPS and 34%POPC:30%POPS:36%Chol liposomes.  
(A) N-terminal sequences of EIAV and HIV-1 mutants adapted with modifications 
from Hatanaka et al (30). Red denotes mutated amino acid residues; blue denotes 
conserved residues. Helix 1 (H1) is marked for each virus. (B) Quantification of EIAV 
mutants and (B) HIV mutants. Binding was performed with two lipid types: 
70%POPC:30%POPS and 34%POPC:30%POPS:36%Chol. EIAV Gag and HIV-1 WT 
Gag results were included to serve as comparisons. Quantification was performed of 
no less than three flotation reactions for each composition. Error bars represent 
standard deviations from the mean. 
 
FIG.3 EIAV Gag-GFP and HIV Gag-GFP mutant virus release from 293T cells.  
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(A) Example of a Western Blot cropped bands of EIAV Gag-GFP and HIV Gag-GFP. 
VLPs were collected from medium 24h post-transfection and compared to lysed cell 
fractions. Amount of Gag-GFP released was analyzed with Western blot analysis. (B) 
Quantification of % Virus release was calculated as the amount of extracellular Gag 
divided by total Gag. Error bars represent standard deviations from the mean from 
three independent experiments. Significance, calculated using an unpaired student 
t-test is shown with asterisks.  
 
FIG. 4. EIAV and HIV Gag-GFP localization in 293T cells.  
293T cells were transfected with (A) EIAV-WT Gag-GFP, (B) EIAV WT Gag G2A GFP, 
(C) HIV-WT Gag-GFP, and (D) HIV-WT A3D Gag-GFP. Images are representative of 
cells after one experiment. 
 
Appendix FIG. 1 Example of eGFP-LactC2 Purification.  
30 L of each fraction during each purification step was loaded. eGFP-LactC2 was by 
using a ppSUMO expression plasmid.  (A) Coomassie-Blue stained SDS-PAGE of 
eGFP-LactC2 purification. Lanes: (1) Ladder (Promega) (2) Post-spin: crude 
supernatant after sonication and centrifugation at 90,000 rpm for 1 h at 4C. 
Supernatant was incubated with NI-NTA beads (QIAGEN) for 2 h at 4C. (3) 
Flowthrough (FT): flowthrough fraction after running supernatant through Ni-NTA 
column (4-7) Washes 1-4 (W1-4). Each wash was performed with 5 mL of Wash 
Buffer. (8) Elution 1 (E1): 10 mL of elution buffer was used to elute SUMO-eGFP-
LactC2 off column. Elution fraction was dialyzed overnight with ULP protease in 20 
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mM Tris, 500 mM NaCl, pH 7 overnight to dilute imidazole. Dialyzed fraction was 
incubated Ni-NTA beads for 2 h at 4C. (9) Flowthrough 2(FT2): flowthrough 
fraction after running dialyzed supernatant through Ni-NTA column. (10) Wash 
(W1): wash was performed with 5 mL of 20 mM Tris, 500 mM NaCl, pH 7. (B) 
Continuation of eGFP-LactC2 purification: Coomassie-Blue stained SDS-PAGE of 
eGFP-LactC2 purification. (1) Ladder. (2) Wash (W2): wash was performed with 5 
mL of dialysis buffer. (3) Elution 1 (E1): eGFP-LactC2 was eluted after incubation for 
30 min at 4C with 5 mL of Wash Buffer. (4) Elution 2 (E2) eGFP-LactC2 with 5 mL 
of Wash Buffer. (5) Elution 3 (E3) eGFP-LactC2 with 5 mL of Elution Buffer.  
 
Appendix FIG.2 Comparison of eGFP-LactC2 binding to silica beads and liposomes 
at different NaCl concentrations.  
(A) Example of Coomassie-Blue stained SDS-PAGE showing eGFP-LactC2 binding to 
100%PC and 90%PC:10%PS silica beads at 100 mM NaCl. Supernatant (S), washes 
(W), and pelleted beads (B) are shown. (B) Example of Coomassie-Blue stained SDS-
PAGE of eGFP-LactC2 binding to 100%PC and 90%PC:10%PS silica beads to a panel 
of 100, 300, 500 mM NaCl to assess effects of electrostatics of eGFP-LactC2 binding. 
(C) Quantification of eGFP-LactC2 binding to 100%PC and 90%PC:10%PS silica 
beads at 100, 300, 500 mM NaCl. Quantification was performed of no less than three 
separate binding reactions for each composition. Error bars represent standard 
deviations from the mean. (D) Coomassie-Blue stained SDS-PAGE of purified eGFP-
LactC2 binding to 100%PC liposomes at 160 and 300 mM NaCl. Top two fractions 
represent membrane bound; bottom two fractions represent non membrane bound 
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fraction. (e) As in D, except with 90%PC:10%PS liposomes. (F) Quantification of 
eGFP-LactC2 binding to 100%PC and 90%PC:10%PS liposomes at 160 and 300 mM 
NaCl. Quantification was performed of no less than three separate flotation 
reactions for each composition. Error bars represent standard deviations from the 
mean.  
 
Appendix FIG. 3 Silica bead binding experiments with surface blockers BSA or cell 
extract (CE).   
(A) Example of SDS-PAGE of eGFP-LactC2 binding to 100%PC and 90%PC:10%PS 
silica beads with BSA as blocking agent. Binding was performed to panel of 100, 300, 
500 mMNaCl. (B) Example of SDS-PAGE of eGFP-LactC2 binding to 100%PC and 
90%PC:10%PS silica beads with CE as blocking agent. Binding was performed to 
panel of 100, 300, 500 mMNaCl. (C) Quantification of eGFP-LactC2 binding to 
100%PC and 90%PC:10%PS silica beads with BSA at 100, 300, 500 mM NaCl. 
Quantification was performed of no less than three separate binding reactions for 
each composition. Error bars represent standard deviations from the mean. (D) 
Quantification of eGFP-LactC2 binding to 100%PC and 90%PC:10%PS silica beads 
with CE at 100, 300, 500 mM NaCl. Quantification was performed of no less than 
three separate binding reactions for each composition. Error bars represent 
standard deviations from the mean. 
 
Supplementary Table 1 List of constructs and primers used in this study. 
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Supplementary Table 1 
 
Construct Cloning done by Forward Primer Reverse Primer 
pET3xc-EIAV WT Steven Chen 
5'- CAC CAT TCT AGA ATG GGA GAC 
CCT TTG ACA TGG- 3' 
5'- CAC CAT GAA TTC TTA CTC CCA 
CAA ACT GTC CAG- 3' 
pET3xc-EIAV G2A Steven Chen 
5'- CAC CAT TCT AGA ATG GCA GAC 
CCT TTG ACA TGG AGC- 3' 
5'- CAC CAT GAA TTC TTA CTC CCA 
CAA ACT GTC CAG- 3' 
pET3xc-EIAV D3A Steven Chen 
5'- CAC CAT TCT AGA ATG GGA GCC 
CCT TTG ACA TGG- 3' 
5'- CAC CAT GAA TTC TTA CTC CCA 
CAA ACT GTC CAG- 3' 
pET3xc-EIAV P4A Steven Chen 
5'- CAC CAT TCT AGA ATG GGA GCC 
GCT TTG ACA TGG- 3' 
5'- CAC CAT GAA TTC TTA CTC CCA 
CAA ACT GTC CAG- 3' 
pET3xc-EIAV D3A P4R Steven Chen 
5'- CAC CAT TCT AGA ATG GGA GCC 
CGT TTG ACA TGG- 3' 
5'- CAC CAT GAA TTC TTA CTC CCA 
CAA ACT GTC CAG- 3' 
pET3xc-HIV WT Rob Dick   
pET3xc-HIV G2A Rob Dick   
pET3xc-HIV A3D Steven Chen 
5'- CAC CAT CAT ATG GGT GAC AGA 
GCG TCA GTA TTA- 3' 
5'- CAC CAT GGT ACC CTA AAA ATT 
CCC TGG- 3' 
pET3xc-RSV WT Rob Dick   
pEGFP N1-EIAV WT Steven Chen 
5'- CAC CAT GAA TTC ATG GGA GAC 
CCT TTG ACA TGG- 3' 
5'- CAC CAT GGA TCC AAC TCC CAC 
AAA CTG TCC AGG TT- 3' 
pEGFP N1-EIAV G2A Steven Chen 
5'- CAC CAT GAA TTC ATG GCA GAC 
CCT TTG ACA TGG- 3' 
5'- CAC CAT GGA TCC AAC TCC CAC 
AAA CTG TCC AGG TT- 3' 
pEGFP N1-EIAV D3A Steven Chen 
5'- CAC CAT GAA TTC ATG GGA GCC 
CCT TTG ACA TGG- 3' 
5'- CAC CAT GGA TCC AAC TCC CAC 
AAA CTG TCC AGG TT- 3' 
pEGFP N1-EIAV P4A Steven Chen 
5'- CAC CAT GAA TTC ATG GGA GAC 
GCT TTG ACA TGG- 3' 
5'- CAC CAT GGA TCC AAC TCC CAC 
AAA CTG TCC AGG TT- 3' 
pEGFP N1-EIAV D3A 
P4R Steven Chen 
5'- CAC CAT GAA TTC ATG GGA GCC 
CGT TTG ACA TGG- 3' 
5'- CAC CAT GGA TCC AAC TCC CAC 
AAA CTG TCC AGG TT- 3' 
pEGFP N1-HIV WT Rob Dick   
pEGFP N1-HIV G2A Marc Johnson   
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pEGFP N1-HIV A3D Steven Chen 
5'- CAC CAT GAA TTC ATG GGT GAC 
AGA GCG TCA GTA TTA- 3' 
5'- CAC CAT GGA TCC AAA ATT CCC 
TGG CCT TCC CTT GTA- 3' 
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